Compare OWLT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | XGN |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 110.7M |
| IPO Year | 2020 | 2014 |
| Metric | OWLT | XGN |
|---|---|---|
| Price | $4.89 | $7.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.50 | $8.86 |
| AVG Volume (30 Days) | 237.1K | ★ 261.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $105,708,000.00 | N/A |
| Revenue This Year | $22.81 | $8.12 |
| Revenue Next Year | $20.45 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 35.43 | N/A |
| 52 Week Low | $4.19 | $2.59 |
| 52 Week High | $16.94 | $12.23 |
| Indicator | OWLT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 58.60 |
| Support Level | $4.70 | $4.08 |
| Resistance Level | $6.23 | $7.99 |
| Average True Range (ATR) | 0.31 | 0.40 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 6.43 | 28.34 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.